CORRECTION: Last week, I flagged a study that looked at prices for generic drugs at a number of “direct to consumer” pharmacies. I noted that the researchers compared the prices
One of the great freedoms of the newsletter format is that they can be as long or as short as they need to be. So while I’m going to be
I guess I’m supposed to write about the Senate HELP hearing yesterday. I’ve certainly wasted a bunch of pixels in the runup. It would be weird if I ignored it
It’s a short newsletter today because my attention will be on Washington today. I plan to watch as much of the Senate hearing as I can stand. There’s a lot
I can only think of one time in my life when a congressional hearing about health care was actually illuminating. It was 2016, and Mylan CEO Heather Bresch testified on
If we’re being honest, the force that is going to end the ever-escalating trend of PBM-fueled rebates and the accompanying shell game is probably not going to be legislative action,
For more than a quarter-century, I’ve been a member of the National Association of Science Writers, a group that does great work supporting a broad range of folks who write
Scheduling Note: The plan is for Cost Curve to be off tomorrow, back Monday. If any IRA prices leak, though, I’ll be back at it. I was kind of bummed